Bibliographic citations
Vega, J., (2024). Eficacia y seguridad de la Azitromicina para prevenir sepsis y muerte neonatal: Revisión sistemática y metaanálisis [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/54151
Vega, J., Eficacia y seguridad de la Azitromicina para prevenir sepsis y muerte neonatal: Revisión sistemática y metaanálisis [Tesis]. PE: Universidad Privada Antenor Orrego; 2024. https://hdl.handle.net/20.500.12759/54151
@misc{renati/1051191,
title = "Eficacia y seguridad de la Azitromicina para prevenir sepsis y muerte neonatal: Revisión sistemática y metaanálisis",
author = "Vega Vargas, Juan Jesús Martín",
publisher = "Universidad Privada Antenor Orrego",
year = "2024"
}
To determine the efficacy and safety of azithromycin compared to placebo in preventing sepsis and neonatal death. Materials and methods: A systematic search of six databases for clinical trials comparing the efficacy and safety of azithromycin for sepsis and neonatal death was performed. The primary outcomes assessed were the development of sepsis and neonatal mortality. The secondary outcome was treatment safety as assessed by reported adverse events. Relative risk (RR) measures were used as a measure of outcome estimation. Results: Four clinical trials involving 42,235 newborns were included. The rate of neonatal sepsis was 7.3% for the group receiving azithromycin and 7.2% for the group receiving placebo (RR: 1.03; IC 95%: 0.96-1.10; p = 0.47; I 2 = 0%). The neonatal mortality rate was 1.3% for the group receiving azithromycin and 1.3% for the group receiving placebo (RR: 1.02; IC 95%: 0.86-1.20; p = 0.84; I 2 = 0%). Conclusion: Compared to placebo, azithromycin does not reduce neonatal sepsis and mortality. Further studies in low-resource clinical settings are needed to establish the utility of this intervention
This item is licensed under a Creative Commons License